Both active and inactive ingredients in topical ophthalmic agents may cause allergic contact dermatitis. Here, we examined ingredients in prescription topical ophthalmic medications available in the United States.
Methods
A comprehensive list of topical ophthalmic medications was generated using AccessPharmacy. Categories included antiglaucoma, antibiotic, antibiotic/corticosteroid, corticosteroid, antiviral, antifungal, mydriatic, and miotic agents. For each formulation, ingredients were investigated using the National Institutes of Health US National Library of Medicine database and/or manufacturer websites. Counts and proportions were calculated for inactive ingredients, including those in the American Contact Dermatitis Society (ACDS) Core 90 Allergen Series.
Results
Two hundred sixty-four unique prescription ophthalmic medications met the inclusion criteria. The most common ACDS Core 90 allergen/cross-reactor inactive ingredient was benzalkonium chloride (68.1%, 180/264), followed by sorbates (11.7%, 31/264), parabens (6.8%, 18/264), sodium metabisulfite (3.8%, 10/264), propylene glycol (3.0%, 8/264), and lanolin (3.0%, 8/264). Approximately 21% (20.8%, 55/264) of products had no ACDS Core 90 allergens/cross-reactor inactive ingredients. The most common ACDS Core 90 allergen/cross-reactor active ingredients were aminoglycoside antibiotics, bacitracin/polymyxin B, and corticosteroids. Important non–ACDS Core 90 allergens included inactive ingredients, such as EDTA 28.0% and thimerosal 2.7%, as well as active ingredients, especially β-blockers.
Conclusions
Benzalkonium chloride, sodium metabisulfite, propylene glycol, and lanolin were common inactive ingredient allergens. Most ophthalmic categories had low allergen formulations available for patients with contact allergy.
Get full access to this article
View all access options for this article.
References
1.
AminKA, BelsitoDV. The aetiology of eyelid dermatitis: a 10-year retrospective analysis. Contact Dermatitis, 2006; 55(5):280–285.
2.
GilissenL, De DeckerL, HulshagenT, et al.Allergic contact dermatitis caused by topical ophthalmic medications: keep an eye on it!. Contact Dermatitis, 2019; 80(5):291–297.
3.
OmA, YeungH, de la FeldS. Prevalence of contact allergens in best-selling ophthalmic products [published online September 8, 2020]. Dermatitis, 2020.
4.
CoopmanS, DegreefH, Dooms-GoossensA. Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol, 1989; 121:27–34.
5.
BaeckM, ChemelleJA, GoossensA, et al.Corticosteroid cross-reactivity: clinical and molecular modelling tools. Allergy, 2011; 66(10):1367–1374.
6.
Cruzval-O'ReillyE, Lugo-SomolinosA. Keep an eye out for loteprednol etabonate: a new steroid allergy. Dermatitis, 2020; 31(5):e50–e51.
7.
HedengranA, SteensbergAT, VirgiliG, et al.Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively pre- served and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis. Br J Ophthalmol, 2020; 104(11):1512–1518.
8.
UterW, LessmannH, GeierJ, et al.Is the irritant benzalkonium chloride a contact allergen? A contribution to the ongoing debate from a clinical perspective. Contact Dermatitis, 2008; 58(6):359–363.
9.
LechienJR, Costa de AraujoP, De MarrezLG, et al.Contact allergy to benzalkonium chloride in patients using a steroid nasal spray: a report of 3 cases. Ear Nose Throat J, 2018; 97(1–2):E20–E22.
10.
ChiambarettaF, PouliquenP, RigalD. Allergy and preservatives. Apropos of 3 cases of allergy to benzalkonium chloride [in French]. J Fr Ophtalmol, 1997; 20(1):8–16.
11.
LandeckL, JohnSM, GeierJ. Topical ophthalmic agents as allergens in periorbital dermatitis. Br J Ophthalmol, 2014; 98(2):259–262.
12.
YanochkoGM, Khoh-ReiterS, EvansMG, et al.Comparison of preservative-induced toxicity on monolayer and stratified Chang conjunctival cells. Toxicol In Vitro, 2010; 24(4):1324–1331.
13.
SchlarbaumJP, HylwaSA. Allergic contact dermatitis to operating room scrubs and disinfectants. Dermatitis, 2019; 30(6):363–370.
SoschinD, LeydenJJ. Sorbic acid-induced erythema and edema. J Am Acad Dermatol, 1986; 14(2 pt 1):234–241.
16.
GöranssonK, LidénS. Contact allergy to sorbic acid and Unguentum Merck. Contact Dermatitis, 1981; 7(5):277.
17.
ClemmensenO, HjorthN. Perioral contact urticaria from sorbic acid and benzoic acid in a salad dressing. Contact Dermatitis, 1982; 8(1):1–6.
18.
FranswayAF, FranswayPJ, BelsitoDV, et al.Parabens. Dermatitis, 2019; 30(1):3–31.
19.
PraditsuwanP, TaylorJS, RoenigkHHJr. Allergy to Unna boots in four patients. J Am Acad Dermatol, 1995; 33(5 pt 2):906–908.
20.
DeKovenJG, WarshawEM, ZugKA, et al.North American Contact Dermatitis Group patch test results: 2015–2016. Dermatitis, 2018; 29(6):297–309.
21.
ReederM, AtwaterAR. Parabens: the 2019 nonallergen of the year. Cutis, 2019; 103(4):192–193.
22.
García-GavínJ, ParenteJ, GoossensA. Allergic contact dermatitis caused by sodium metabisulfite: a challenging allergen: a case series and literature review. Contact Dermatitis, 2012; 67(5):260–269.
23.
SeitzCS, BröckerEB, TrautmannA. Eyelid dermatitis due to sodium metabisulfite. Contact Dermatitis, 2006; 55(4):249–250.
HigginsCL, NixonRL. Periorbital allergic contact dermatitis caused by lanolin in a lubricating eye ointment. Australas J Dermatol, 2016; 57(1):68–69.
27.
HätinenA, TeräsvirtaM, FräkiJE. Contact allergy to components in topical ophthalmologic preparations. Acta Ophthalmol, 1985; 63(4):424–426.
28.
NguyenHL, YianniasJA. Contact dermatitis to medications and skin products. Clin Rev Allergy Immunol, 2019; 56(1):41–59.
29.
LyonCC, BeckMH. Allergic contact dermatitis reactions to corticosteroids in periorbital inflammation and conjunctivitis. Eye (Lond), 1998; 12(pt 1):148–149.
30.
BaeckM, De PotterP, GoossensA. Allergic contact dermatitis following ocular use of corticosteroids. J Ocul Pharmacol Ther, 2011; 27(1):83–92.
31.
GuptaR, HylwaS, ZirwasM, et al.Defining topical corticosteroids by allergenicity and cross-reactivity for the Contact Allergen Management Program. Dermatitis, 2020; 31(4):e45–e46.
32.
BarberKA.Allergic contact eczema to phenylephrine. Contact Dermatitis, 1983; 9:274–277.
33.
DucombsG, De CasamayorJ, VerinP, et al.Allergic contact dermatitis to phenylephrine. Contact Dermatitis, 1986; 15:107–108.
34.
YoshikawaK, KawaharaS. Contact allergy to atropine and other mydriatic agents. Contact Dermatitis, 1985; 12:56–51.
35.
Van Der WilligenAH, De GraafYP, Van JoostT. Periocular dermatitis from atropine. Contact Dermatitis, 1987; 17:56–57.
De GrootAC, ConemansJ. Contact allergy to metipranolol. Contact Dermatitis, 1988; 18:107–108.
40.
SchultheissE.Hypersensitivity to levobunolol [in German]. Derm Beruf Umwelt, 1989; 37:185–186.
41.
HoldinessMR.Contact dermatitis to topical drugs for glaucoma. Am J Contact Dermat, 2001; 12(4):217–219.
42.
JappeU, UterW, Menezes de PáduaCA, et al.Allergic contact dermatitis due to beta-blockers in eye drops: a retrospective analysis of multicentre surveillance data 1993–2004. Acta Derm Venereol, 2006; 86(6):509–514.
43.
JerstadKM, WarshawE. Allergic contact dermatitis to latanoprost. Am J Contact Dermat, 2002; 13(1):39–41.
ShimadaM, HigakiY, KawashimaM. Allergic contact dermatitis due to dorzolamide eyedrops. Contact Dermatitis, 2001; 45(1):52.
47.
SwansonLA, WarshawEM. Allergic contact dermatitis to topical brimonidine tartrate gel 0.33% for treatment of rosacea. J Am Acad Dermatol, 2014; 71(4):832–833.
48.
Millan-ParrillaF, De La CuadraJ. Allergic contact dermatitis from trifluoridine in eyedrops. Contact Dermatitis, 1990; 22:289.
49.
MathiasCGT, MaibachHI, IrvineA, et al.Allergic contact dermatitis to echothiophate iodide and phenylephrine. Arch Ophthalmol, 1979; 97(2):286–287.
KangH, ChoiJ, LeeAY. Allergic contact dermatitis to white petrolatum. J Dermatol, 2004; 31(5):428–430.
58.
PrestonPW, FinchTM. Allergic contact dermatitis from glycerin in a moisturizing cream. Contact Dermatitis, 2003; 49(4):221–222.
59.
SuzukiR, FukuyamaK, MiyazakiY, et al.Contact urticaria syndrome and protein contact dermatitis caused by glycerin enema. JAAD Case Rep, 2016; 2(2):108–110.
60.
SakakibaraS, KawabeY, MizunoN. Photoallergic contact dermatitis due to mineral oil. Contact Dermatitis, 1989; 20(4):291–294.
61.
García-MedinaJJ, García-MedinaM, Zanon-MorenoVC, et al.Conjunctival provocation test for the diagnosis ofocular hypersensitivity to chlorobutanol. Cornea, 2007; 26(1):94–97.
62.
GreyKR, WarshawEM. Allergic contact dermatitis to ophthalmic medications: relevant allergens and alternative testing methods. Dermatitis, 2016; 27(6):333–347.
63.
BrancaccioRR, MilburnPB, SilviE. Iatrogenic contact dermatitis to proparacaine: an ophthalmic topical anesthetic. Cutis, 1993; 52(5):296–298.
64.
DannakerCJ, MaibachHI, AustinE. Allergic contact dermatitis to proparacaine with subsequent cross-sensitization to tetracaine from ophthalmic preparations. Am J Contact Dermat, 2001; 12(3):177–179.
65.
DavisMDP.Unusual patterns in contact dermatitis: medicaments. Dermatol Clin, 2009; 27(3):289–297.
